Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Cavo M, et al. Among authors: facon t. Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101. Blood. 2022. PMID: 34289038 Free PMC article. Clinical Trial.
Double-intensive therapy in high-risk multiple myeloma.
Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, Casassus P, Guilhot F, Ifrah N, Gandhour C. Harousseau JL, et al. Among authors: facon t. Blood. 1992 Jun 1;79(11):2827-33. Blood. 1992. PMID: 1350228 Free article.
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL. Moreau P, et al. Among authors: facon t. J Clin Oncol. 1997 Feb;15(2):660-6. doi: 10.1200/JCO.1997.15.2.660. J Clin Oncol. 1997. PMID: 9053491 Clinical Trial.
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.
Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N, Harousseau JL. Moreau P, et al. Among authors: facon t. Br J Haematol. 1998 Jun;101(4):766-9. doi: 10.1046/j.1365-2141.1998.00772.x. Br J Haematol. 1998. PMID: 9674753 Free article.
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A, Schroyens W, Hulin C, Schots R, Marin P, Guilhot F, Granena A, De Waele M, Pigneux A, Méresse V, Clark P, Reiffers J. Facon T, et al. Blood. 1999 Aug 15;94(4):1218-25. Blood. 1999. PMID: 10438709 Free article. Clinical Trial.
P53 deletion is not a frequent event in multiple myeloma.
Avet-Loiseau H, Li JY, Godon C, Morineau N, Daviet A, Harousseau JL, Facon T, Bataille R. Avet-Loiseau H, et al. Among authors: facon t. Br J Haematol. 1999 Sep;106(3):717-9. doi: 10.1046/j.1365-2141.1999.01615.x. Br J Haematol. 1999. PMID: 10468863 Free article.
423 results